Schering Plough

The company is leader in 8 therapeutic classes as antihistamines and all classes of corticosteroids. The core businesses are respiratory system, dermatology, anti-inflammatories, anti-infectives, oncology and over-the-counter (including sun care, cough and cold, and nasal decongestants).

Activity:

- Clinical Trials
- Contract Manufacturing
- Contract Research
- Licensing & Business Development
- Manufacturing
- Research & Development
- Sales & Distribution
- Other Industry Services

Product / Technology type(s) covered:

- Bio
- Cosmoceuticals
- Curative
- Generics
- FP (finished products)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Phyto
- Nutritionals / Vitamins
- Prescription drugs (Rx)
- Preventive
- Proteins

Therapeutic targets:

- Aging
- AIDS
- Allergy
- Alzheimer's Disease
- Arthritis / Rheumato
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Genetics
- Geriatrics
- Hematology
- Infectious Diseases
- Men's Health
- Mental Health
- Neurology
- Obesity
- Oncology
- Ophthalmology
- Orthopedics
- Pain
- Pediatrics
- Radiology
- Respiratory Medicine
- Stroke
- Tonics
- Transplant
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: Brazil

b. Continent(s) active: Central/South America

c. Countries active: Brazil

Corporate data:

Number of Employees: 1200

Turnover:

Amount:	Year:	Currency:
50	2005	US Dollar

Year founded: 1975

Partners / Alliances: Schering-Plough Brazil is a joint-venture between Schering-Plough Corporation and national investors who have the control of the company. Therefore, the company has autonomy for licensing and developing its own products. Schering-Plough Brazil is the 5th pharmaceutical company in prescriptions on the Brazilian market. We hold a 3,32% share of the Brazilian pharmaceutical market and rank 6 with a 200 million dollars sale and 80 million units a year.